What’s Next With New Ketamine Depression Drug? At IOL, a Study With Kids.

Ketamine
Print icon

While the nation is clamoring for more information about the new treatment approved by the Food and Drug Administration for depression, Drs. Andrew Winokur and Mirela Loftus are quietly working on the next application.

A nasal spray containing the active ingredient Esketamine — a chemical “relative” of the drug ketamine that has served as an anesthetic for decades – was approved for use against severe (treatment resistant) cases of depression in adults. Dr. Loftus, a child and adolescent psychiatrist, has been part of a research team affiliated with the Institute of Living testing various applications of the drug, marketed as Spravato, for depression.

The initial results in patients, she said, are astonishing,

“There are people who have been in our study for two or three years and every one of them has had the same story about how life-changing this is for them,” Dr. Loftus said.

Esketamine alters the chemical functioning of the brain in a manner that is different from antidepressant drugs currently on the market. Besides affecting the chemical shift in the brain that sparks depression, Esketamine works on the glutamate, affecting the synaptic plasticity. In other words, it potentially changes the connections or synapses in the brain that contribute to depression.

“The mechanism of action here is very different than any other anti-depression medication on the market now,” Dr. Loftus said.

A controlled substance, Esketamine must be administered in an approved clinic environment in which the patient is monitored for an hour or two for any adverse reaction. Such reactions, she said, can include elevated blood pressure and an altered perception of reality such as dissociation, dizziness, sleepiness or seeing double.

A variety of questions about the medication remain, however, and Dr. Loftus said researchers will continue to seek answers. For example, while there have been appropriate concerns about abuse potential related to the inappropriate use of ketamine (sometimes referred to as Special K), in carefully controlled clinical trials of Esketamine, problems with dependence or abuse have not been identified to date, although more research on this topic is needed.

“There has not been a long enough period of observation to know the answer to that,” she began. “But, why would I give a drug of abuse? It’s a completely different way of delivery and dosing than in the street.”

She is also involved in other research projects through the IOL’s Clinical Trials Unit, including one investigating the use of Esketamine in children and adolescents.

“The IOL is one of the few sites in the world using this in children and adolescents. We just recruited the second adolescent in the world for our study,” Dr. Loftus said, noting that the work is focused on children and adolescents presenting with suicidal thoughts, the most severe form of depression.

In addition, the IOL team is hoping to discover how to shorten the patient reaction time to the medication. Currently, Esketamine takes a few days to show an effect, as opposed to weeks for existing antidepressants. Further research is needed to see if there are certain conditions in which the effect would be even shorter, even just hours.

For more information about treatment for depression at the Hartford HealthCare Behavioral Health Network, click here. For learn more about the Institute of Living’s Clinical Trials Unit, click here.

 

 


What's New

Overweight woman talking to medical professional.

Weight Loss, From Diet to Surgery: Which is Right for You?

Managing your weight is challenging, but it is one of the most important steps you can take for a healthier lifestyle. Dr. Pavlos Papasavas is director of research in the department of surgery and co-director of bariatric surgery at Hartford Hospital: Q.  First, can you explain the different approach to...


Three Veterans Receive Wartime Service Medals at Mulberry Gardens

Many people remember their 21st birthdays. However, few individuals celebrate like Marjorie McKennerney did on her 21st in 1944: she enlisted in the U.S. Navy. “We were all very patriotic at that time. We all wanted our country to win the war,” she said, explaining why she felt compelled to...


The Hospital of Central Connecticut Opens New Cardiac Rehabilitation Space

The Hospital of Central Connecticut Cardiac Rehabilitation Program has opened a new rehabilitation space on its New Britain campus. The 3,120-square-foot facility provides the latest equipment to aid in the treatment and recovery of cardiac patients. The center provides phase II telemetry monitored exercise to patients who have been treated...

Poison Oak

5 Common Summer Rashes and How to Prevent Them

One of the most common causes for a summer visit to the doctor’s office is a rash. Although a sudden outcropping of skin bumps and lumps can be disturbing to anyone, summer rashes are often treated effectively. A rash that appears suddenly and spreads quickly on both sides of the...

ADHD

Not Just for Kids: What it Takes To Be Diagnosed With ADHD as an Adult

Attention-Deficit/Hyperactivity Disorder, when correctly diagnosed in children, often lingers into adulthood, but for others it’s only then that it manifests itself for the first time. Michael Stevens, PhD, of the Olin Neuropsychiatry Research Center at the Institute of Living in Hartford, said ADHD in adults is only slightly less common...